Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05321420 · ClinicalTrials.gov registry record · Phase 2
LYT-100 in Patients With Idiopathic Pulmonary Fibrosis (IPF)
A Phase 2 study of Idiopathic Pulmonary Fibrosis, sponsored by PureTech.
- Active
- Registry status
- Phase 2
- Development phase
- 240
- Enrollment target
- 20
- Study locations
NCT05321420 is a Phase 2 study of Idiopathic Pulmonary Fibrosis that is active but no longer recruiting, run by PureTech. The registered enrollment target is 240 participants, below the 747-participant average among 51 other Idiopathic Pulmonary Fibrosis trials with a reported enrollment target (68% lower). The trial reports 20 study locations across 12 states.
The verdict
NCT05321420, a Phase 2 study of Idiopathic Pulmonary Fibrosis, is active but no longer recruiting, sponsored by PureTech.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 240 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study a randomized, double-blind, four arm study to evaluate the safety and efficacy of LYT-100 compared to pirfenidone or placebo in adults with Idiopathic Pulmonary Fibrosis.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Pirfenidone
- DRUG Deupirfenidone
Study Locations (20)
California
- Science 37 - Los Angeles
- NewportNativeMD, Inc. - Newport Beach
- Paradigm Clinical Research Centers, Inc. - Redding
- Los Angeles Biomedical Research Institute at Harbor UCLA Medical Center - Torrance
Florida
- Accel Research Sites Network - DeLand
- Harmony Medical Research Institute, Inc - Hialeah
Georgia
- Piedmont Healthcare, Inc. - Atlanta
- Clinical Research Investments - Decatur
North Carolina
- Pulmonix - Greensboro
- Southeastern Research Center - Winston-Salem
Tennessee
- Clinical Trials Center of Middle Tennessee - Franklin
- Vanderbilt University Medical Center - Nashville
Texas
- Baylor Scott & White Research Institute - Dallas
- Renovatio Clinical - The Woodlands Research Center - The Woodlands
Alabama
- University of Alabama Birmingham - Birmingham
Connecticut
- University of Connecticut Health Center - Farmington
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 240 participants |
| Start Date | 2022-07-22 |
| Est. Completion | 2025-12-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05321420
The ClinicalTrials.gov registry entry for NCT05321420 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 240 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 747-participant average among 51 other Idiopathic Pulmonary Fibrosis trials with a reported enrollment target (68% lower). The listed sponsor is PureTech, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Idiopathic Pulmonary Fibrosis appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT05321420 reports 20 study locations spanning 12 distinct geographic areas - top geographies include California, Florida, Georgia.
Frequently Asked Questions
What is clinical trial NCT05321420 about?
NCT05321420 is a clinical study titled "LYT-100 in Patients With Idiopathic Pulmonary Fibrosis (IPF)". This study a randomized, double-blind, four arm study to evaluate the safety and efficacy of LYT-100 compared to pirfenidone or placebo in adults with Idiopathic Pulmonary Fibrosis.
What is the current status of trial NCT05321420?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 240 participants. The study started on 2022-07-22. Estimated completion is 2025-12-31.
What conditions does trial NCT05321420 study?
This clinical trial studies the following conditions: Idiopathic Pulmonary Fibrosis.
What interventions are being tested in trial NCT05321420?
The interventions under investigation include: Placebo (DRUG), Pirfenidone (DRUG), Deupirfenidone (DRUG).
Who is sponsoring clinical trial NCT05321420?
This trial is sponsored by PureTech, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05321420 being conducted?
This trial has 20 study locations across Alabama, California, Connecticut, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Idiopathic Pulmonary Fibrosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Phase 2 Study of CAL101 in Patients With Idiopathic Pulmonary Fibrosis
RECRUITING · Phase 2
-
Zinc and Nicotinamide Riboside for Idiopathic Pulmonary Fibrosis
RECRUITING · Phase 2
-
A Study to Find Out Whether BI 765423 Has an Effect on Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF) With or Without Standard Treatment
RECRUITING · Phase 2
-
A Study in People With Idiopathic Pulmonary Fibrosis to Test Whether Pirfenidone Influences the Amount of BI 1015550 in the Blood
RECRUITING · Phase 2
-
WISPer: Evaluation of MTX-463 in Participants With Idiopathic Pulmonary Fibrosis (IPF)
RECRUITING · Phase 2
-
H01 in Adults With Interstitial Lung Disease (The SOLIS Study)
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.